Traditional claims data alone, however, cannot answer many of these critical questions
Glucose-affecting peptides: GH secretagogues can raise blood sugar
If you don't get enough, you may experience symptoms of deficiency like fatigue, weakness, or nerve damage
Over the past few years, GLP-1 receptor agonistsincluding Ozempic (semaglutide) and Mounjaro (tirzepatide)have been prohibitively expensive for many people without generous insurance coverage
In prior studies, it was found that these two classes of drugs showed heart and kidney benefits besides controlling blood sugar.[3] The researchers analyzed data from six previous trials of GLP-1 (including a total of 51,762 subjects) and four trials of SGLT2 inhibitors (including 33,457 subjects)
However, its important to note that these findings are based on data aggregated from various published papers, and differences in the drugs used, frequency of administration, and experimental designs make direct comparison challenging and not entirely conclusive (Figure 5)